Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toca 8: Toca 511 and Toca FC in Recurrent High Grade Non-Muscle Invasive Bladder Cancer
NCT04089163Phase 1Withdrawn
- Sponsor
- Tocagen
- Start
- Dec 2019
- Primary completion
- Jan 2022
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
01
Overview
Phase 1, open-label, single-arm trial of vocimagene amiretrorepvec in non-muscle-invasive bladder cancer (NMIBC), sponsored by Tocagen. Primary endpoint: Dose-limiting toxicities at 5 weeks. Planned start Dec 2019; status: withdrawn.
02
Drugs
vocimagene amiretrorepvec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04089163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04089163.